Evidence map›Paper›PMID 31957347›Full record

ArticleAnnals of clinical and translational neurology2020

CSF SerpinA1 in Creutzfeldt-Jakob disease and frontotemporal lobar degeneration.

Samir Abu-Rumeileh, Steffen Halbgebauer, Petra Steinacker, Sarah Anderl-Straub, Barbara Polischi, Albert C Ludolph, Sabina Capellari, Piero Parchi, Markus Otto

Open access · goldAbstract read
In one paragraph

Article in Annals of clinical and translational neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 27 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. MScience signaling · 2022
    Article
  9. Article
  10. Article
  11. Serpin neuropathology in the P497S UBQLN2 mouse model of ALS/FTD.Brain pathology (Zurich, Switzerland) · 2021
    Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Samir Abu-Rumeileh *Department of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, 40139, Bologna, Italy.ORCID 0000-0003-0631-8506
Steffen Halbgebauer *Department of Neurology, Ulm University Hospital, 89081, Ulm, Germany.
Petra SteinackerDepartment of Neurology, Ulm University Hospital, 89081, Ulm, Germany.
Sarah Anderl-StraubDepartment of Neurology, Ulm University Hospital, 89081, Ulm, Germany.
Barbara PolischiIRCCS Istituto delle Scienze Neurologiche di Bologna, 40139, Bologna, Italy.
Albert C LudolphDepartment of Neurology, Ulm University Hospital, 89081, Ulm, Germany.ORCID 0000-0002-5401-0904
Sabina CapellariDepartment of Biomedical and NeuroMotor Sciences (DIBINEM), University of Bologna, 40139, Bologna, Italy.
Piero ParchiIRCCS Istituto delle Scienze Neurologiche di Bologna, 40139, Bologna, Italy.ORCID 0000-0002-9444-9524
Markus OttoDepartment of Neurology, Ulm University Hospital, 89081, Ulm, Germany.
University Hospital Ulm · DEIstituto delle Scienze Neurologiche di Bologna · ITUniversity of Bologna · IT

Funding

BIU D.5009EU Joint Programme - Neurodegenerative Disease Research (JPND) networkGerman Federal Ministry of Education and Research FTLDc 01GI1007AItalian Ministry of Health Ricerca correntePreFrontAls 01ED1512the foundation of the state of Baden-Württemberg D.3830the Thierry Latran foundation
6 · The paper itself

Abstract

objectiveSerpinA1 (alpha-1 antitrypsin) is an acute inflammatory protein, which seems to play a role in neurodegeneration and neuroinflammation. In Alzheimer's disease and synucleinopathies, SerpinA1 is overexpressed in the brain and the cerebrospinal fluid (CSF) showing abnormal patterns of its charge isoforms. To date, no comprehensive studies explored SerpinA1 CSF isoforms in Creutzfeldt-Jakob disease (CJD) and frontotemporal lobar degeneration (FTLD).

methodsUsing a capillary isoelectric focusing immunoassay, we analyzed CSF SerpinA1 isoforms in control cases (n = 31) and patients with a definite or probable diagnosis of CJD (n=77) or FTLD (n = 30), belonging to several disease subtypes.

resultsThe overall SerpinA1 signal was significantly higher than in controls in CJD subtypes linked to abnormal prion protein (PrP

interpretationCJD linked to PrP

Indexed as

Agedalpha 1-AntitrypsinCreutzfeldt-Jakob SyndromeFemaleFrontotemporal Lobar DegenerationHumansMaleMiddle AgedProtein IsoformsUp-Regulationalpha 1-AntitrypsinProtein Isoforms

Identifiers

PMID31957347
PMCPMC7034504
OpenAlexW3002278484

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.